French biotech Valneva has signed a new $59 million contract with the US Department of Defence for its supply of Japanese encephalitis (JE) vaccine Ixiaro.
Valneva will supply Ixiaro doses to the Defence Logistics Agency of the US Department of Defense through 2019 and the beginning of 2020 with a value of $59 million guaranteed and potentially worth up to $70 million.
A delivery schedule is being prepared and supply shipments will commence immediately.
“We are pleased to continue our important collaboration with the U.S. government to fight this deadly disease,” said Franck Grimaud, Chief Business Officer of Valneva.
“The US military has been using Ixiaro since 2010 and we are excited to further support the expansion of its use and help protect military personnel and their families from Japanese encephalitis.”
Ixiaro is the only JE vaccine approved by the US FDA. It has been developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research.
Valneva markets and distributes Ixiaro directly to the US military and US private market.
In October 2018, the Company announced that the FDA approved an accelerated Ixiaro vaccination schedule of two doses administered seven days apart, compared to the previous 28-day schedule.